Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Bristol-Myers Squibb Company stock (BMY)

Buy Bristol-Myers Squibb Company stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Bristol-Myers Squibb Company is a drug manufacturers - general business based in the US. Bristol-Myers Squibb Company shares (BMY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $53.44 – an increase of 1.02% over the previous week. Bristol-Myers Squibb Company employs 34,100 staff and has a trailing 12-month revenue of around $46.5 billion.

Our top picks for where to buy Bristol-Myers Squibb Company stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Bristol-Myers Squibb Company stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BMY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Latest updates for Bristol-Myers Squibb Company

September 17, 2024: Bristol-Myers Squibb is a stock on the rise and is becoming one of the most searched-for stocks on analyst insight websites like Zacks.com.

Buy Bristol-Myers Squibb Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
eToro
Finder Score: 4 / 5: ★★★★★
EXCLUSIVE
eToro
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.9%
FINDER EXCLUSIVE: Get a guaranteed $15 bonus
No commission stock, ETF and options trades, with 4.9% interest on your options account balance and no options contract fees.
Robinhood
Finder Score: 4.4 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bristol-Myers Squibb Company stock price (NYSE: BMY)

Use our graph to track the performance of BMY stocks over time.

Bristol-Myers Squibb Company shares at a glance

Information last updated 2024-10-07.
Latest market close$53.44
52-week range$38.60 - $54.88
50-day moving average $49.35
200-day moving average $47.78
Wall St. target price$52.30
PE ratio N/A
Dividend yield $2.37 (4.45%)
Earnings per share (TTM) $-3.25

Is it a good time to buy Bristol-Myers Squibb Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bristol-Myers Squibb Company price performance over time

Historical closes compared with the close of $53.44 from 2024-10-07

1 week (2024-10-01) 1.02%
1 month (2024-09-06) 9.73%
3 months (2024-07-08) 33.63%
6 months (2024-04-08) 4.58%
1 year (2023-10-06) -5.68%
2 years (2022-10-07) -16.58%
3 years (2021-10-08) 4.70%
5 years (2019-10-08) 12.85%

Is Bristol-Myers Squibb Company stock undervalued or overvalued?

Valuing Bristol-Myers Squibb Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol-Myers Squibb Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bristol-Myers Squibb Company's PEG ratio

Bristol-Myers Squibb Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0809. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol-Myers Squibb Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Bristol-Myers Squibb Company's EBITDA

Bristol-Myers Squibb Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19 billion.

The EBITDA is a measure of a Bristol-Myers Squibb Company's overall financial performance and is widely used to measure a its profitability.

Bristol-Myers Squibb Company financials

Revenue TTM $46.5 billion
Operating margin TTM 21.29%
Gross profit TTM $36.4 billion
Return on assets TTM 6%
Return on equity TTM -26.59%
Profit margin -14.06%
Book value $8.39
Market Capitalization $108.3 billion

TTM: trailing 12 months

Bristol-Myers Squibb Company share dividends

2%

Dividend payout ratio: 1.9% of net profits

Recently Bristol-Myers Squibb Company has paid out, on average, around 1.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol-Myers Squibb Company shareholders could enjoy a 4.45% return on their shares, in the form of dividend payments. In Bristol-Myers Squibb Company's case, that would currently equate to about $2.37 per share.

While Bristol-Myers Squibb Company's payout ratio might seem low, this can signify that Bristol-Myers Squibb Company is investing more in its future growth.

Bristol-Myers Squibb Company's most recent dividend payout was on 31 October 2024. The latest dividend was paid out to all shareholders who bought their shares by 3 October 2024 (the "ex-dividend date").

Have Bristol-Myers Squibb Company's shares ever split?

Bristol-Myers Squibb Company's shares were split on a 1000000:95 basis on 6 August 2001. So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol-Myers Squibb Company shares – just the quantity. However, indirectly, the new 100% lower share price could have impacted the market appetite for Bristol-Myers Squibb Company shares which in turn could have impacted Bristol-Myers Squibb Company's share price.

Bristol-Myers Squibb Company share price volatility

Over the last 12 months, Bristol-Myers Squibb Company's shares have ranged in value from as little as $38.6043 up to $54.8753. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol-Myers Squibb Company's is 0.46. This would suggest that Bristol-Myers Squibb Company's shares are less volatile than average (for this exchange).

Bristol-Myers Squibb Company overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company.

Frequently asked questions

null
What percentage of Bristol-Myers Squibb Company is owned by insiders or institutions?
Currently 0.111% of Bristol-Myers Squibb Company shares are held by insiders and 77.86% by institutions.
How many people work for Bristol-Myers Squibb Company?
Latest data suggests 34,100 work at Bristol-Myers Squibb Company.
When does the fiscal year end for Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company's fiscal year ends in December.
Where is Bristol-Myers Squibb Company based?
Bristol-Myers Squibb Company's address is: Route 206 & Province Line Road, Princeton, NJ, United States, 08543
What is Bristol-Myers Squibb Company's ISIN number?
Bristol-Myers Squibb Company's international securities identification number is: US1101221083
What is Bristol-Myers Squibb Company's CUSIP number?
Bristol-Myers Squibb Company's Committee on Uniform Securities Identification Procedures number is: 110122108

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site